MEDICLIN Reports Strong Nine-Month Performance with 41.7% Operating Profit Growth
MEDICLIN Aktiengesellschaft demonstrated robust financial performance in the first nine months of 2025, with group operating results surging 41.7% to €48.9 million and sales growing 5.1% to €586.9 million, signaling strong recovery in the healthcare sector despite ongoing cost pressures.
MEDICLIN Aktiengesellschaft reported consolidated group sales of €586.9 million for the first nine months of 2025, representing a 5.1% increase compared to the same period last year. The group operating result showed even stronger growth, rising to €48.9 million from €34.5 million in the previous year, marking a significant 41.7% improvement. Overall capacity utilization across the Group remained stable at 86.8%, slightly above the 86.0% recorded in the same period of 2024.
The post-acute segment emerged as the strongest performer, with sales increasing by 9.3% to €394.6 million and segment operating result rising by €9.6 million to €47.6 million. Despite facing higher personnel expenses, which increased by 9.4% to €205.0 million due to salary increases and additional staffing, the segment maintained its personnel expense ratio at 51.9%. The cost of materials ratio improved, falling by 0.9 percentage points to 19.5%.
In the acute segment, strategic decisions including the sale of the former MEDICLIN Herzzentrum Coswig influenced performance, resulting in a 3.2% decrease in segment sales. However, the segment showed remarkable improvement in profitability, with operating result turning positive at €0.7 million compared to a loss of €3.8 million in the previous year. This represents a 117.2% improvement, achieved through reduced costs of materials and personnel expenses, which declined by 4.8% and 4.8% respectively.
The nursing care segment reported sales of €18.6 million but experienced a decline in operating result to a loss of €0.4 million. Meanwhile, the service segment demonstrated positive momentum with sales increasing to €74.8 million and operating result improving by €0.8 million to €1.0 million. The interim report as of 30 September 2025 is available in German and English at https://www.mediclin.de.
The Management Board confirmed its guidance for the full 2025 financial year, expecting consolidated group sales growth between 2.0% and 5.0% and consolidated group EBIT between €53.0 million and €64.0 million. Tino Fritz, CFO of MEDICLIN, commented that despite current market conditions and typical seasonal effects in the fourth quarter, the company continues to assess business development as solid and expects to achieve its original annual guidance. The original release can be viewed on https://www.newmediawire.com.